Qualigen Therapeutics Inc.

QLGN | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.21

$0.00 (0.00%)

Nov 2, 2026, 3:52 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.00%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Sep 30, 2026

18.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $5.43M

1D Range

2.86 3.34

52W Range

1.61 8.81

Valuation (TTM)

PE -0.51

PB 0.96

EV/EBITDA -0.30

Valuation (NTM)

Forward PE N/A

Forward PEG 0.01

Price Target N/A

Cash Flow

FCF Yield -224.7%

SBC Adj. FCF Yield -224.7%

SBC Impact N/A

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -150.0% | -75.3%

Dil EPS 3Y | 5Y -59.7% | -2.2%

FCF 3Y | 5Y -31.8% | 7.7%

Returns

ROA -344.0%

ROE -108.3%

ROIC -281.2%

Financial Health

Net Cash

$537.77K

Current Ratio 3.68

Interest Coverage -19.89

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing groundbreaking treatments for both cancer and infectious diseases. In addition to its developmental pipeline, the company...

Sector Healthcare

Industry Biotechnology

Employees 4

IPO Date Jun 23, 2015

Website qlgntx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.